Medicine and HealthNature Communications
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID-19
B. Boras, R. M. Jones, et al.
Discover how PF-07304814, a groundbreaking phosphor prodrug of the potent 3CL protease inhibitor PF-00835231, could revolutionize COVID-19 treatment. With impressive antiviral effects and promising synergy with remdesivir, this innovative research, conducted by a team including Britton Boras and Dan Arenson, paves the way for new therapeutic options against coronaviruses.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration
G. T. Y. Yau, W. Tai, et al.
Medicine and Health
Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia
M. E. Layton, J. C. Kern, et al.
Medicine and Health
An artificial intelligence system for predicting the deterioration of COVID-19 patients in the emergency department
F. E. Shamout, Y. Shen, et al.
Psychology
An energizing role for motivation in information-seeking during the early phase of the COVID-19 pandemic
Y. Abir, C. B. Marvin, et al.
